Introduction
first proposed the term ''Ocular surface squamous neoplasia (OSSN)'' to encompass the spectrum of dysplasia, carcinoma in situ and squamous cell carcinoma of ocular surface i.e., conjunctiva, limbus and cornea [1] .It is the third most common ocular tumor after retinoblastoma and melanoma (1, 2) .OSSN is more common in elderly males in tropical countries due to over exposure to sun light. Diagnosis of OSSN is mainly based on clinical suspicion and confirmed by histopathological evaluation. Prevalence of OSSN varies from 0.03-1.9 per million population depending on the geographic location [3] .Risk factors for OSSN include ultraviolet light exposure, fair skin, human papilloma virus (HPV) infection, human immune deficiency virus (HIV) infection, and cigarette smoking, increased p53 expression, chronic inflammatory diseases of the ocular surface such as mucous membrane pemphigoid, chronic blepharoconjunctivitis, and atopic eczema [1, 4 ] .Recently, immuno histochemically detectable p53 protein, bcl-2 protein, MIB-1 are being used as markers of proliferative potency having a possible prognostic value. MIB-1 is a monoclonal antibody that recognizes Ki-67 antigen which is a marker of cell proliferation.Bcl-2 is a proto oncogene which is thought to have a role in oncogenesis by inhibiting programmed cell death and preserving cells from p53 induced apoptosis. p53 gene is a common cellular target in human carcinogenesis and thought to have an important role in cellular proliferation. The interplay between the effects of the mutant p53, absence of bcl-2 expression and enhanced expression of MIB-1 are believed to contribute to the progression of OSSN.
II. Clinical Features
OSSN typically presents as a growth on the ocular surface and gives rise to symptoms like foreign body sensation, redness or irritation and rarely, diminution of vision due to high astigmatism or involvement of visual axis. It usually starts in interpalpebral conjunctiva and then grows and straddles the limbus and then may or may not involve the cornea. OSSN lesions mostly are slightly elevated and have a pearly grey appearance 
Morphological Classification
Conjunctival Lesions 1. Gelatinous-Circumscribed gelatinous lesions are the most common. The nodular type is rapidly growing with a high incidence of metastasis to adjacent lymphnodes. The diffuse type is the least common and in the early stages presents as persistent redness of the conjunctiva are slow growing and mimic chronic conjunctivitis. It is difficult to differentiate between benign and malignant lesions in these cases. 2. Leucoplakic-These are usually pre invasive. 3. Papiliform-These type typically are exophytic, strawberry like, with a stippled red appearance corresponding to its fibro vascular core. They are clinically benign.
Corneal Lesions
Corneal OSSN lesions are pre invasive, with a mottled ground glass sheet appearance which is opalescent. They have sharply defined fimbriated borders, the convex leading edge spreads in an arc away from the limbus and often white dots are present over the grey epithelium. They are usually avascular. These lesions are typically indolent, slow growing and prone to recurrence. 
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Diagnosis -A high index of clinical suspicion is necessary. An incision / excision biopsy is considered the 'gold standard' for diagnosis and planning further treatment. Impression cytology with Biopore membrane has reasonably good accuracy but can miss about 20% of cases. However it has a definite role in follow-up of lesions, after primary treatment, whether surgical or topical chemotherapy. 5, 8, 9 III.
Materials & Methods
14 patients over a period of 6 months with histopathologically proven OSSN were reviewed. In each case a complete medical and surgical taken, ocular examination including location, extent and clinical history was appearance of the lesion was done. The lesions were surgically excised keeping a safe margin of 2-3 mm of normal appearing conjunctiva. Cryotherapy was applied to the resected conjunctival margin and limbus with rapid freeze and slow thaw technique. If scleral involvement was seen, partial lamellar sclerotomy was done and the scleral bed was treated with absolute alcohol. Surgical reconstruction if required was done with conjunctival autograft. After initial epithelial healing, patients were recommended to have regular examinations in every 2 months for 1 year and annually thereafter.
IV. Results And Discussion
Clinically, the diagnosis of OSSN is suspected by the appearance of epithelial changes of the ocular surface. Slit-lamp examination shows gelatinous, leukoplakic, papilliform or nodular lesions. Histopathological evaluation is essential for the definitive diagnosis and also to differentiate the three lesions in the spectrum of OSSN i.e., epithelial dysplasia, carcinoma in situ and invasive squamous cell carcinoma. Though OSSN is considered as a localized, slow growing lesion with low metastatic potential, intraocular, intra orbital and distant metastasis do occur rarely. OSSN has intraocular and orbital extension rate of 4%, regional and distant metastasis rate of 1.2%, and a mortality rate of 0.8%. Sites of metastasis include the preauricular, submandibular, and cervical lymph nodes, the parotid gland, lungs, and bones. Regional lymph node involvement precedes the development of distant metastases. [10] The main cause for metastasis is delay in diagnosis and treatment. [3] Surgical excision with ''wide margin, no touch'' technique is currently the best established form of treatment. Nevertheless, recurrences of these lesions are common after surgical excision, depending on the involvement of the surgical margins. Recurrence rates following excision of OSSN alone range from 15 to 52%, with an average of 30%. Recurrence rate is 5% when the surgical margins are free and 53% when the surgical margins are involved. [11] Adjunctive therapy to reduce recurrence includes intra operative cryotherapy and brachytherapy, postoperative topical chemotherapy using mitomycin C, 5-FU and interferon alfa-2.
